MH1 OUTCOMES ASSOCIATED WITH THE IMPLEMENTATION OF A DOSE OPTIMIZATION PROGRAM FOR ATYPICAL ANTIPSYCHOTIC MEDICATIONS IN A MANAGED CARE ORGANIZATION  by Dunn, JD et al.
A14 Abstracts
diabetes/100,000) were identiﬁed, projecting to a national ESI
rate of 4814/100,000. Over half of all diabetics had drug treat-
ment; 854.6/100,000 with insulin, 1,536.1/100,000 with sul-
fonylurea, and 2,427.6/100,000 with other treatments, including
metformins, TZDs, and combination products. Annual health
care expenditures for diabetics, with or without drug treatment,
was $14,138. Annual expenditures were $23,223, $14,045, and
$13,252, for patients treated with insulins, sulfonulureas, and
other treatments, respectively. CONCLUSION: Reliable esti-
mates of the prevalence, treatment and cost of diabetes and other
conditions, are valuable to policy makers, providers, and payers.
Individuals with ESI represent over 56% of the U.S. population,
a large group with fewer cost barriers to care. This study demon-
strates a reliable projection methodology for estimating disease
prevalence, treatment events, and costs associated with any
disease or condition based on a large convenience sample of
health care claims data.
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OBJECTIVES: To evaluate the impact of identifying and inter-
vening upon inefﬁcient dosing practices related to atypical
antipsychotics in a large commercial managed care organization.
METHODS: An analysis using the Interactive Prescribing Efﬁ-
ciency Tool (iPET) was conducted to identify inefﬁcient pre-
scribing among atypical antipsychotics. Pill combinations used
to reach all daily doses for the atypicals were identiﬁed and base-
line opportunity cost savings calculated. A pharmacy claims edit
was instituted for all atypicals on July 1, 2004. Prescriptions
were ﬂagged at the pharmacy level if inefﬁcient dosing was
present and automatic optimization of regimens was imple-
mented based on predetermined algorithms. The iPET was used
to reevaluate the success of this intervention at improving eco-
nomic outcomes. RESULTS: We identiﬁed 1215 patients receiv-
ing an atypical antipsychotic during the pre-intervention period
(aripiprazole n = 153; olanzapine n = 284; quetiapine n = 469;
risperidone n = 289; ziprasidone n = 81). Some patients may have
received multiple atypicals. Inefﬁcient pill combinations may
have been received by 7.8%, 18.7%, 27.9%, 27.7%, and 23.5%
of aripiprazole, olanzapine, quetiapine, risperidone, and ziprasi-
done patients, respectively. An opportunity savings of $157,401
in overall atypical antipsychotic expenditures was estimated (if
up to 70% of inefﬁcient doses were converted to more efﬁcient
pill combinations). In the period after the dose optimization
program had been implemented, we identiﬁed 1166 patients as
receiving an atypical (aripiprazole n = 158; olanzapine n = 258;
quetiapine n = 463, risperidone n = 250; ziprasidone n = 80).
During this period, inefﬁcient pill combinations may have 
been received by 4.4%, 8.5%, 38.9%, 10.0%, and 20% of aripi-
prazole, olanzapine, quetiapine, risperidone, and ziprasidone
patients, respectively. The opportunity savings dropped to
$58,385 indicating a costs savings of $99,016 following the
implementation of the dose optimization intervention. CON-
CLUSIONS: Substantial improvements in economic outcomes
were realized through an intervention focused on increasing pre-
scribing efﬁciency among the atypical antipsychotics.
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OBJECTIVES: To compare the health care costs and hospital-
ization days of elderly major depressive disorder (MDD) patients
treated with escitalopram to those treated with other SSRI/SNRI.
METHODS: Elderly MDD patients (age °Y´65) initiated on esc-
italopram or other SSRI/SNRI were identiﬁed in the IHCIS
National Managed Care Database (2003 ¨C 2005). Health care
costs and hospitalization days were compared between patients
on escitalopram to those on other SSRI/SNRI over 6 months fol-
lowing therapy initiation (study period). Wilcoxon tests were
used to compare the costs descriptively. Diff-in-diff analyses were
conducted to control for baseline (the 6 months prior to therapy
initiation) costs. GLM regression with log link function was used
for total health care cost comparison. Negative binomial regres-
sion was used to compare the number of hospitalization days.
Both regressions adjusted for patient demographics, comorbidi-
ties, and medical resource use at baseline. Costs were inﬂation
adjusted to 2005 US dollars. RESULTS: The study sample
included 459 elderly MDD patients initiated on escitalopram and
1517 patients initiated on other SSRI/SNRI. Descriptive analy-
ses showed that patients on escitalopram had $2143 lower six-
month total health care costs than patients on other SSRI/SNRI
(p = 0.398), and about half of the difference was from lower hos-
pitalization costs ($1271, p = 0.145). After adjusting for base-
line costs using the diff-in-diff method, the difference in total
health care costs became signiﬁcant ($2319, p = 0.037), and
about one third of the difference was from lower hospitalization
costs ($806, p = 0.036). The GLM regression showed that the
six-month total health care costs of patients on escitalopram 
was $3120 less than patients on other SSRI/SNRI (p = 0.001). 
Negative binomial regression showed that patients on escitalo-
pram had 39% less hospitalization days (p = 0.004). CON-
CLUSION: Compared to elderly MDD patients initiated on
other SSRI/SNRI, patients who initiated escitalopram have lower
health care costs and less hospitalization.
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OBJECTIVES: Patients with schizophrenia commonly suffer
from clinically relevant co-morbidities, including alcoholism,
substance abuse, and hepatitis, that may compromise hepatic
function. The study was designed to evaluate the prevalence of
liver diseases in patients with schizophrenia as compared to non-
mentally ill controls. METHODS: South Carolina State Medic-
aid program data were analyzed. Patients <65 years, with a
schizophrenia diagnosis (ICD-9CM) from January 2002 to
December 2003 were identiﬁed. A 4 : 1 random selection algo-
rithm (4 without diagnosis to 1 with diagnosis) was applied.
Prevalence of liver diseases was assessed from ambulatory or
hospital claims over the 24-month period (January 2004–
December 2005) and compared between the two groups. The
liver disease related ICD-9CM codes included 570–573.xx,
070.xx, 782.4, 790.4, 794.8 for acute liver disease, alcoholic
